Study of HSK42360 for brain tumors with BRAF V600 mutation in children
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new drug, HSK42360, for children with recurrent brain tumors that have a specific gene change called BRAF V600. The goal is to see if the drug can help when standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 17 years old.
- Your brain tumor has come back after standard treatment and has a specific gene change (BRAF V600 mutation).
- You are able to perform daily activities with minimal help (performance status score above 60).
- You have not had other cancer in the last 2 years (except for some low-risk types).
- Your heart, liver, kidneys, and blood counts are working well enough.
- You are not pregnant or breastfeeding, and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HSK42360, for people with advanced solid tumors that have a specific gene change called BRAF V600. It may be an option if other treatments have stopped working.
This is an early-stage study testing a new investigational drug (HSK42360-Na) designed to target a specific genetic mutation (BRAF V600) found in some advanced or metastatic cancers. The goal is to see if this drug is safe and effective for patients whose cancers have grown despite prior treatments.
This trial tests an experimental drug (HSK42360-Na) combined with standard treatments (cetuximab with or without chemotherapy) for people with advanced colorectal cancer that has a specific BRAF mutation. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
This trial tests whether a new oral drug called FCN-159 works better than standard chemotherapy for children and teens with a slow-growing brain tumor (low-grade glioma) that has a specific change in the BRAF gene. The goal is to see if FCN-159 can shrink the tumor or stop it from growing.
This Phase 1 trial tests KH617, a new treatment, in adults with advanced cancers to see if it can be given safely and whether it shows signs of benefit. It is especially focused on tumors that have few or no standard treatment options, including certain brain tumor recurrences.
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
Hear when a new Malignant Brain Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.